Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2026 | What is currently understood about the role of hormonal changes in Parkinson’s disease?

Katarina Rukavina • 29 Jun 2026
EAN 2026
Movement Disorders Parkinson's Disease

Katarina Rukavina, MD, PhD, Movement Disorders Hospital, Beelitz, Germany, discusses the current understanding of the role of hormonal changes in Parkinson’s disease (PD). Dr Rukavina explains the role of estrogen in PD, highlighting key evidence and clinical implications. This interview took place at the 12th Congress of the European Academy of Neurology (EAN) in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Katarina Rukavina

When menopause and Parkinson's symptoms overlap: guidance for earlier recognition
2:02
When menopause and Parkinson's symptoms overlap: guidance for earlier recognition
Katarina Rukavina • 29 Jun 2026
Medically assisted dying and palliative care in neurological disorders
1:39
Medically assisted dying and palliative care in neurological disorders
Katarina Rukavina • 20 Apr 2026
Striatal dopaminergic deficiency as a biomarker for personalized treatment in early PD
1:28
Striatal dopaminergic deficiency as a biomarker for personalized treatment in early PD
Katarina Rukavina • 20 Apr 2026
Real-world outcomes of foslevodopa/foscarbidopa infusion in advanced Parkinson’s disease
4:46
Real-world outcomes of foslevodopa/foscarbidopa infusion in advanced Parkinson’s disease
Katarina Rukavina • 21 Apr 2026

Related Videos

When menopause and Parkinson's symptoms overlap: guidance for earlier recognition
2:02
When menopause and Parkinson's symptoms overlap: guidance for earlier recognition
Katarina Rukavina • 29 Jun 2026
Ongoing research into foslevodopa/foscarbidopa in PD treatment
4:47
Ongoing research into foslevodopa/foscarbidopa in PD treatment
K. Ray Chaudhuri • 30 Jun 2026
A discussion at EAN 2026 on the impact of climate change on neurological diseases
13:26
A discussion at EAN 2026 on the impact of climate change on neurological diseases
Amalia Ghergu et al. • 28 Jun 2026
Development and Phase III trial results of levacetylleucine for ataxia-telangiectasia
8:08
Development and Phase III trial results of levacetylleucine for ataxia-telangiectasia
Michael Leo Strupp • 29 Jun 2026
The content of VJNeurology is intended for healthcare professionals